Search
cenobamate (Xcopri)
Indications:
- partial-onset seizures in adults
Dosage:
- begin 12.5 mg PO QD titrate
- titrate every 2 weeks, QD dosin
Tabs: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg
Adverse effects:
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) when cenobamate rapidly titrated
- shortening of the QT interval
- suicidal ideation
- somnolence, dizziness, fatigue, diplopia, headache.
Interactions
drug adverse effects of anticonvulsants
monitor with anticonvulsants
General
anticonvulsant
References
- FDA News Release. Nov 21, 2019
FDA approves new treatment for adults with partial-onset seizures.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-partial-onset-seizures
- FDA Approves XCOPRI(cenobamate tablets), an Anti-Epileptic Drug (AED) from
SK Biopharmaceuticals, Co.,Ltd.,andU.S. Subsidiary SK Life Science, Inc
https://www.sklifescienceinc.com/pdf/FDA_Approves_XCOPRI_(cenobamate_tablets)_an_Anti-Epileptic_Drug_(AED)_from_SK_Biopharmaceuticals_Co._Ltd._and_U.S._Subsidiary_SK_Life_Science_Inc.pdf